ARS Wealth Advisors Group 13F: New $217K Stake in GILD

ARS Wealth Advisors Group has opened a new position in Gilead Sciences, Inc. (GILD), acquiring 1,458 shares valued at approximately $217,280 in a filing on October 16, 2026. This marks the fund's first stake in Gilead, reflecting its interest in the biopharmaceutical sector.

What Changed in ARS Wealth Advisors Group's Position

ARS Wealth Advisors Group took a new position by acquiring 1,458 shares of Gilead Sciences. This is a new buy for the fund, which had no previous holdings in the company.

Other Institutional Activity in Gilead Sciences

Several other institutional investors have also recently held or adjusted their stakes in Gilead Sciences. Blackrock Inc. owns 121,844,108 shares valued at about $19.03 billion after increasing its holdings by 2,832,477 shares. Vanguard Capital Management LLC has 81,091,734 shares worth approximately $12.67 billion, having added 435,543 shares. FMR, LLC reduced its stake by 5,033,287 shares, bringing its total to 66,870,816 shares valued at about $10.44 billion.

Gilead Sciences, Inc. Stock Down 1.0%

Recently trading around $155.84, Gilead's stock is above its 50-day moving average by 6.5% and its 200-day average by 13.0%. However, it sits about 2.9% below its 52-week high of $160.51. This positioning indicates a mix of stability and potential upward pressure in the coming months.

Recent Earnings

Gilead Sciences reported trailing twelve-month revenue of $30.46 billion, reflecting a year-over-year growth rate of 10.2%. The company's earnings per share (EPS) stands at -$2.65, indicating challenges in profitability. The next earnings report is scheduled for October 29, 2026.

Insider Buying and Selling at Gilead Sciences, Inc.

Insider transactions show that several executives sold shares earlier in the year. Director Anthony Welters sold 18,000 shares on August 26, 2026, while CEO Daniel Patrick O'Day sold 15,000 shares on September 1, 2026. These trades were executed ahead of the recent 13F filing.

Analysts Set New Price Targets

Analysts have maintained positive ratings on Gilead Sciences. On October 7, 2026, Truist Securities maintained a Buy rating with a price target of $158. JP Morgan and Morgan Stanley also kept their ratings at Overweight, with targets of $170 and $163, respectively. The consensus price target among analysts is $159.85, suggesting potential growth from current prices.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that discovers and develops medicines for various medical needs. Its products focus on areas such as HIV-1 treatment, with notable offerings including Biktarvy and Descovy. This new investment by ARS Wealth Advisors Group comes at a time when Gilead is navigating its financial performance and market position.

Bottom Line

Investors will want to keep an eye on Gilead Sciences, especially with the next earnings report coming up on October 29, 2026. The 13F filing reflects holdings as of the reporting period and may not represent current positions.